Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.

Article English OPEN
Christopher J A Duncan; Susanne H Sheehy; Katie J Ewer; Alexander D Douglas; Katharine A Collins; Fenella D Halstead; Sean C Elias; Patrick J Lillie; Kelly Rausch; Joan Aebig; Kazutoyo Miura; Nick J Edwards; Ian D Poulton; Angela Hunt-Cooke; David W Porter; Fiona M Thompson; Ros Rowland; Simon J Draper; Sarah C Gilbert; Michael P Fay; Carole A Long; Daming Zhu; Yimin Wu; Laura B Martin; Charles F Anderson; Alison M Lawrie; Adrian V S Hill; Ruth D Ellis;
  • Publisher: Public Library of Science (PLoS)
  • Journal: PLoS ONE,volume 6,issue 7 (issn: 1932-6203, eissn: 1932-6203)
  • Related identifiers: doi: 10.1371/journal.pone.0022271, pmc: PMC3142129
  • Subject: Research Article | Biology | Vaccine Development | Tropical Diseases (Non-Neglected) | Vaccines | Clinical Research Design | Infectious Diseases | Microbiology | Medicine | Immunity | Malaria | Q | R | Plasmodium Falciparum | Clinical Immunology | Immunizations | Science | Parastic Protozoans | Protozoology | Clinical Trials | Public Health | Vaccination
    mesheuropmc: parasitic diseases

Background Inhibition of parasite growth is a major objective of blood-stage malaria vaccines. The in vitro assay of parasite growth inhibitory activity (GIA) is widely used as a surrogate marker for malaria vaccine efficacy in the down-selection of candidate blood-stag... View more
Share - Bookmark